But it was for allegedly anti-competitive behaviors, in keeping other contraceptive ring manufacturers at bay inside the country -- all aimed at keeping selling prices high (on the legacy Organon products). Here is the latest, from FiercePharma:
. . .Merck has been hit with a fine in Spain for alleged anti-competitive practices. The Spanish antitrust watchdog National Commission on Markets and Competition (CNMC) has docked the New Jersey pharma giant 39 million euros ($38.45 million) for hindering a generic version of its NuvaRing contraceptive device.
The agency said that Merck used deceptive practices in preventing Insud Pharma of Spain from marketing its device. The U.S. company also obtained a court order that barred Insud from manufacturing its generic in Spain, the CNMC said, which effectively prevented Insud from selling the device anywhere in the world.
. . .Merck said it disagrees with the ruling and is considering options including an appeal. . . .
The case dates to 2018 when. . . [regulators said Merck was abusing the global patent processes] “in order to delay and hinder the entry into the market of third-party competitors in Spain. . . .”
Oh -- and Mr. Davis -- a competent (if uninspiring, and non-charismatic) leader. . . has become the Chairman, as well -- with Mr. Frazier's final curtain call effective December 1, 2022. Now you know. . . smiling.
नमस्ते
No comments:
Post a Comment